Our findings indicate that a high frequency of Treg cells along with a high level of TGF-β one week after anti-PD-1 immunotherapy could be used as favorable blood-based biomarkers at an early point in the therapy of advanced NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.